-
HORIZON PHARMA, INC. et al v. LUPIN LTD. et al DC CAFC
- 2:11-cv-04275
- D.N.J.
- Judge: Stanley R. Chesler
+2
- Filed: 07/25/2011
- Closed: 10/15/2012
- Latest Docket Entry: 09/25/2019
- PACER
5
Plaintiffs
2
Defendants
2
Accused
Products
2
Patents-in-Suit
449
Days in
Litigation
-
HORIZON PHARMA, INC. et al v. LUPIN LTD. et al DC CAFC
- 2:11-cv-04275
- D.N.J.
- Judge: Stanley R. Chesler
+2
- Filed: 07/25/2011
- Closed: 10/15/2012
- Latest Docket Entry: 09/25/2019
- PACER
Market Sector
Biotech and Pharma
Court
Referred Judges
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
5 |
The pharmaceutical composition of claim 1, wherein said acid inhibitor is a proton pump inhibitor selected from the group consisting of: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
|
Valid
Entry 93 |
15 |
The pharmaceutical composition of any one of claims 1 or 7-14, wherein said acid inhibitor is a proton pump inhibitor.
|
Valid
Entry 93 |
52 |
The method of claim 51, wherein said pain or inflammation is due to either osteoarthritis or rheumatoid arthritis.
|
Valid
Entry 93 |
53 |
The pharmaceutical composition of any one of claims 5-11 wherein said unit dosage form is a multilayer tablet comprising a single core and one or more layers outside of said single core, wherein: i) said NSAID is present in said core; ii) said
view more
|
Valid
Entry 93 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical composition in unit dosage form comprising therapeutically effective amounts of: (a) esomeprazole, wherein at least a portion of said esomeprazole is not surrounded by an enteric coating; and (b) naproxen surrounded by a coating that
view more
|
Valid
Entry 93 |
2 |
The pharmaceutical composition of claim 1, wherein naproxen is present in said unit dosage form in an amount of 200-600 mg.
|
Valid
Entry 93 |
3 |
The pharmaceutical composition of claim 1, wherein esomeprazole is present in said unit dosage form in an amount of from 5 to 100 mg.
|
Valid
Entry 93 |
4 |
The pharmaceutical composition of claim 1, wherein naproxen is present in said unit dosage form in an amount of between 200-600 mg and esomeprazole in an amount of from 5 to 100 mg per unit dosage form.
|
Valid
Entry 93 |
-
Infringement
Lupin Limited
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic 375 mg naproxen/20 mg esomeprazole magnesium, 500 mg naproxen/20 mg esomeprazole magnesium delayed release tablets | US 6,926,907 B2 |
5, 15, 52, 53
|
Infringement
Entry 93
|
Generic 375 mg naproxen/20 mg esomeprazole magnesium, 500 mg naproxen/20 mg esomeprazole magnesium delayed release tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 93
|
Lupin Pharmaceuticals Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic 375 mg naproxen/20 mg esomeprazole magnesium, 500 mg naproxen/20 mg esomeprazole magnesium delayed release tablets | US 6,926,907 B2 |
5, 15, 52, 53
|
Infringement
Entry 93
|
Generic 375 mg naproxen/20 mg esomeprazole magnesium, 500 mg naproxen/20 mg esomeprazole magnesium delayed release tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 93
|